{"podcast":{"title":"BackTable Urology","slug":"backtable-urology-3724776","podcast_index_feed_id":3724776,"rss_url":"https://feeds.megaphone.fm/BTL2162345307","website_url":"https://www.backtable.com/shows/urology","image_url":"https://megaphone.imgix.net/podcasts/245977a2-1baf-11ec-bf5c-871fad6d7280/image/BT-Urology-Favicon-Square-3000.png?ixlib=rails-4.3.1&max-w=3000&max-h=3000&fit=crop&auto=format,compress","author":"BackTable LLC","episode_count":317,"summary":"The BackTable Urology Podcast is a resource for practicing urologists to learn tips, techniques, and practical advice from their peers in the field. Listen here or on the streaming platform of your choice.","last_synced_at":"2026-07-21T16:17:19.449101+00:00","page_url":"https://stenobird.com/podcast/backtable-urology-3724776"},"episode":{"title":"Ep. 303 PARP Inhibitors: Clinical Trials & Real-World Applications with Dr. Neeraj Agarwal and Dr. Arun Azad","slug":"ep-303-parp-inhibitors-clinical-trials-real-world-applications-with-dr-neeraj-agarwal-and-dr-arun-azad","published_at":"2026-05-19T07:00:00+00:00","page_url":"https://stenobird.com/podcast/backtable-urology-3724776/ep-303-parp-inhibitors-clinical-trials-real-world-applications-with-dr-neeraj-agarwal-and-dr-arun-azad","show_page_url":"https://stenobird.com/podcast/backtable-urology-3724776","url":"https://traffic.megaphone.fm/BTL2282179957.mp3","audio_url":"https://traffic.megaphone.fm/BTL2282179957.mp3","summary":"Keeping patients on PARP inhibitors long enough to see real benefit often comes down to proactive side effect management. In this episode of BackTable Urology, Dr. Neeraj Agarwal and Dr. Arun Azad join host Dr. Alan Tan to discuss practical, evidence-based strategies for managing hematologic and GI toxicities in advanced prostate cancer patients receiving PARP inhibitors. --- Get the BackTable apphttps://www.backtable.com/app --- This podcast is supported by an educational grant from Pfizer. --- Timestamps 00:00 - Introduction06:17 - Managing Anemia11:12 - Side Effect Profiles19:33 - Transfusions vs ESAs26:43 - Docetaxel vs PARP Inhibitors30:27 - Side Effect Management Pearls40:18 - Team Based Monitoring52:27 - Tissue Versus Liquid01:01:24 - Genetic Counseling Workflow01:07:07 - Trial Equity and Access --- More about this episode The doctors discuss the importance of close anemia monitoring during the critical first 3 to 4 months of therapy, maintaining dose intensity, proactive antiemetic use, and the role of exercise and resistance training in combating fatigue. The conversation also covers differences in toxicity profiles between PARP agents, the value of multidisciplinary care teams, molecular advances in molecular and germline testing, and the evolving landscape of emerging therapies in prostate care. --- Resources Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trialhttps://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00684-1/abstract BRCAAway: A randomized phase 2 trial of abiraterone, olaparib, or abiraterone + olaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) bearing homologous recomb…","meta_description":"Keeping patients on PARP inhibitors long enough to see real benefit often comes down to proactive side effect management. In this episode of BackTable Uro…","key_points":[],"chapters":[],"topics":[],"duration_seconds":4529,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/backtable-urology-3724776/episodes/ep-303-parp-inhibitors-clinical-trials-real-world-applications-with-dr-neeraj-agarwal-and-dr-arun-azad/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/backtable-urology-3724776/ep-303-parp-inhibitors-clinical-trials-real-world-applications-with-dr-neeraj-agarwal-and-dr-arun-azad.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}